Information  X 
Enter a valid email address

JPMorgan Chase & Co (80GT)

  Print      Mail a friend

Friday 12 October, 2018

JPMorgan Chase & Co

JPMC&Co Form 8-K dated Oct 12, 2018 (3Q2018 prstn)

RNS Number : 9505D
JPMorgan Chase & Co
12 October 2018
 

Regulatory Announcement

JPMorgan Chase & Co.

October 12, 2018

JPMorgan Chase & Co. has submitted the following document to the National Storage Mechanism of the UK Listing Authority:

•     Current Report on Form 8-K of JPMorgan Chase & Co. dated October 12, 2018 containing the slides furnished for an investor presentation held on October 12, 2018 to review JPMorgan Chase & Co.'s 2018 third quarter earnings, as furnished to the U.S. Securities and Exchange Commission

 

This Current Report on Form 8-K may also be viewed on the U.S. Securities and Exchange Commission's website (www.sec.gov) and on JPMorgan Chase & Co.'s investor relations website (http://investor.shareholder.com/jpmorganchase/).

For further information, please contact:

Molly Carpenter

Corporate Secretary

JPMorgan Chase & Co.

Telephone number: +001 212 270 6000

Fax number: +001 212 270 4240

Email: [email protected]

DISCLAIMER -- INTENDED ADDRESSEES

Please note that the information contained in the above mentioned document(s) may be addressed to and/or targeted at persons who are residents of particular countries (specified in such document(s)) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom such document(s) is not addressed. Prior to relying on the information contained in such document(s) you must ascertain from the document(s) whether or not you are part of the intended addressees of the information contained therein. 

Your right to access this service is conditional upon complying with the above requirement.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DOCEASEAFANPFFF

a d v e r t i s e m e n t